Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. BROCADE3 was a randomized, double-blind, placebo-controlled, phase 3 trial done at 147 hospitals in 36 countries. Median progression-free survival was 14.5 months in the veliparib group versus 12.6 months in a control group.

Gamma knife radiosurgery for uveal melanomas and metastases: a systematic review and meta-analysis

Gamma knife radiosurgery is used to treat intracranial tumours and intraocular malignancies. We searched MEDLINE and Embase for studies published between Sept 1, 1960, and Feb 1, 2020. We used local tumour control and tumour regression as the primary outcomes.

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

Cabazitaxel significantly improved radiographic progression-free survival and overall survival in the CARD study. The study involved 62 clinical sites across 13 European countries. Patients with metastatic castration-resistant prostate cancer were treated with docetaxel and an androgen signaling-targeted inhibitor. 255 patients were randomly assigned to cabazitaxel or abiraterone or enzalutamide. The Median follow-up was 9 months.

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Surufatinib showed superior efficacy in extrapancreatic neuroendocrine tumors. Eligible patients were adults with progressive, advanced, well-differentiated pancreatic NETs. One on-treatment death in the placebo group was attributed to disease progression.

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

CH5126766 is a novel MEK-pan-RAF inhibitor. The initial development of this drug was limited by toxicity. We evaluated three intermittent oral schedules (28-day cycles) in patients with solid tumors. Eight patients died during the trial due to disease progression.

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

This report provides updated 4-year efficacy, initial overall survival, and late-emergent safety results. Patients aged 15 years or older with resected stage IIIB–C or IV melanoma were randomly assigned (1:1) to receive nivolumab or ipilimumab. 4- year recurrence-free survival was 51% with nvolumac and 76% with ipillumab.

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Trastuzumab was administered intravenously every 3 weeks for 18 doses or weekly for 9 weeks. 5-year distant metastasis-free survival rates were 98% for low-risk, medium-risk, and high-risk patients. It could be used in the neoadjuvant setting, especially in the HER2-positive setting.

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

POETIC was an open-label, multicentre, parallel-group, randomized, phase 3 trial done in 130 UK hospitals. Postmenopausal women aged at least 50 years with hormone receptor-positive, operable breast cancer were randomly assigned (2:1) to POAI or no POAI. POAI has not been shown to improve treatment outcome, but can be used without detriment to help select appropriate adjuvant therapy.

Departments

Recent Posts